Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunotherapy: new insights].

M Geissler1, R Weth

  • 1Abteilung Innere Medizin II, Medizinische Universitätsklinik Freiburg.

Praxis
|February 5, 2003
PubMed
Summary
This summary is machine-generated.

New cancer immunotherapies show promise, with gene-based vaccines and dendritic cell approaches advancing. Future research must correlate clinical responses with immune effectors for optimized treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

ESMO open·2024
Same author

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial.

ESMO open·2023
Same author

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).

Journal of cancer research and clinical oncology·2020
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Cancer immunotherapy, autoimmune diseases, and chronic viral infections are emerging fields.
  • Current immunostimulatory strategies show modest clinical success.
  • Advances in understanding tumor immunity and identifying tumor antigens enable new therapeutic designs.

Purpose of the Study:

  • To review novel immunotherapeutic approaches against tumors.
  • To highlight gene-based cellular cancer immune vaccines.
  • To discuss challenges and future directions in cancer immunotherapy.

Main Methods:

  • Review of existing literature on cancer immunotherapy.
  • Analysis of whole-cell vaccines, dendritic cell-based immunotherapy, and peptide vaccines.

Related Experiment Videos

  • Discussion of new immunological techniques for single-cell analysis of T cells.

    • Main Results:

    • Gene-based cellular cancer immune vaccines are a promising development.
    • Clinical trials demonstrate the general safety of current strategies.
    • A lack of correlation data between clinical responses and antitumoral immune effectors exists.

    Conclusions:

    • Further research is needed to correlate clinical responses with immune effectors.
    • New techniques allow single-cell characterization of antigen-specific T cells.
    • Standardization of clinical trials and identification of immune parameters are crucial for optimizing cancer immunotherapy.